PURPOSE: To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in primary cytogenetically normal acute myeloid leukemia (CN-AML). PATIENTS AND METHODS: Four hundred fifteen previously untreated adults were analyzed for DNMT3A mutations and established prognostic gene mutations and expression markers. Gene- and microRNA-expression profiles were derived using microarrays. RESULTS: Younger (< 60 years; n = 181) and older (≥ 60 years; n = 234) patients had similar frequencies of DNMT3A mutations (35.3% v 33.3%). Missense mutations affecting arginine codon 882 (R882-DNMT3A) were more common (n = 92; 62%) than those affecting other codons (non-R882-DNMT3A). DNMT3A-mutated patients did not differ regarding complete remission rate, but had shorter disease-free survival (DFS; P = .03) and, by trend, overall survival (OS; P = .07) than DNMT3A-wild-type patients. In multivariable analyses, DNMT3A mutations remained associated with shorter DFS (P = .01), but not with shorter OS. When analyzed separately, the two DNMT3A mutation types had different significance by age group. Younger patients with non-R882-DNMT3A mutations had shorter DFS (P = .002) and OS (P = .02), whereas older patients with R882-DNMT3A mutations had shorter DFS (P = .005) and OS (P = .002) after adjustment for other clinical and molecular prognosticators. Gene- and microRNA-expression signatures did not accurately predict DNMT3A mutational status. CONCLUSION: DNMT3A mutations are frequent in CN-AML, and their clinical significance seems to be age dependent. DNMT3A-R882 mutations are associated with adverse prognosis in older patients, and non-R882-DNMT3A mutations are associated with adverse prognosis in younger patients. Low accuracy of gene- and microRNA-expression signatures in predicting DNMT3A mutation status suggested that the role of these mutations in AML remains to be elucidated.
PURPOSE: To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in primary cytogenetically normal acute myeloid leukemia (CN-AML). PATIENTS AND METHODS: Four hundred fifteen previously untreated adults were analyzed for DNMT3A mutations and established prognostic gene mutations and expression markers. Gene- and microRNA-expression profiles were derived using microarrays. RESULTS: Younger (< 60 years; n = 181) and older (≥ 60 years; n = 234) patients had similar frequencies of DNMT3A mutations (35.3% v 33.3%). Missense mutations affecting arginine codon 882 (R882-DNMT3A) were more common (n = 92; 62%) than those affecting other codons (non-R882-DNMT3A). DNMT3A-mutated patients did not differ regarding complete remission rate, but had shorter disease-free survival (DFS; P = .03) and, by trend, overall survival (OS; P = .07) than DNMT3A-wild-type patients. In multivariable analyses, DNMT3A mutations remained associated with shorter DFS (P = .01), but not with shorter OS. When analyzed separately, the two DNMT3A mutation types had different significance by age group. Younger patients with non-R882-DNMT3A mutations had shorter DFS (P = .002) and OS (P = .02), whereas older patients with R882-DNMT3A mutations had shorter DFS (P = .005) and OS (P = .002) after adjustment for other clinical and molecular prognosticators. Gene- and microRNA-expression signatures did not accurately predict DNMT3A mutational status. CONCLUSION:DNMT3A mutations are frequent in CN-AML, and their clinical significance seems to be age dependent. DNMT3A-R882 mutations are associated with adverse prognosis in older patients, and non-R882-DNMT3A mutations are associated with adverse prognosis in younger patients. Low accuracy of gene- and microRNA-expression signatures in predicting DNMT3A mutation status suggested that the role of these mutations in AML remains to be elucidated.
Authors: K H Metzeler; A Walker; S Geyer; R Garzon; R B Klisovic; C D Bloomfield; W Blum; G Marcucci Journal: Leukemia Date: 2011-11-29 Impact factor: 11.528
Authors: Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner Journal: Blood Date: 2005-07-28 Impact factor: 22.113
Authors: Guido Marcucci; Kati Maharry; Susan P Whitman; Tamara Vukosavljevic; Peter Paschka; Christian Langer; Krzysztof Mrózek; Claudia D Baldus; Andrew J Carroll; Bayard L Powell; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544
Authors: Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner Journal: N Engl J Med Date: 2008-05-01 Impact factor: 91.245
Authors: Susan P Whitman; Amy S Ruppert; Michael D Radmacher; Krzysztof Mrózek; Peter Paschka; Christian Langer; Claudia D Baldus; Jing Wen; Frederick Racke; Bayard L Powell; Jonathan E Kolitz; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: Blood Date: 2007-10-16 Impact factor: 22.113
Authors: Susan P Whitman; Amy S Ruppert; Guido Marcucci; Krzysztof Mrózek; Peter Paschka; Christian Langer; Claudia D Baldus; Jing Wen; Tamara Vukosavljevic; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Michael A Caligiuri; Clara D Bloomfield Journal: Blood Date: 2007-03-06 Impact factor: 22.113
Authors: Adam J Mead; David C Linch; Robert K Hills; Keith Wheatley; Alan K Burnett; Rosemary E Gale Journal: Blood Date: 2007-04-24 Impact factor: 22.113
Authors: F Ostronoff; M Othus; P A Ho; M Kutny; D E Geraghty; S H Petersdorf; J E Godwin; C L Willman; J P Radich; F R Appelbaum; D L Stirewalt; S Meshinchi Journal: Leukemia Date: 2012-06-22 Impact factor: 11.528
Authors: Yan Guo; Stephen A Strickland; Sanjay Mohan; Shaoying Li; Amma Bosompem; Kasey C Vickers; Shilin Zhao; Quanhu Sheng; Annette S Kim Journal: Leuk Lymphoma Date: 2017-01-13
Authors: David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley Journal: Cancer Cell Date: 2014-03-20 Impact factor: 31.743
Authors: Guido Marcucci; Kati S Maharry; Klaus H Metzeler; Stefano Volinia; Yue-Zhong Wu; Krzysztof Mrózek; Deedra Nicolet; Jessica Kohlschmidt; Susan P Whitman; Jason H Mendler; Sebastian Schwind; Heiko Becker; Ann-Kathrin Eisfeld; Andrew J Carroll; Bayard L Powell; Jonathan E Kolitz; Ramiro Garzon; Michael A Caligiuri; Richard M Stone; Clara D Bloomfield Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: H Itonaga; D Imanishi; Y-F Wong; S Sato; K Ando; Y Sawayama; D Sasaki; K Tsuruda; H Hasegawa; Y Imaizumi; J Taguchi; H Tsushima; S Yoshida; T Fukushima; T Hata; Y Moriuchi; K Yanagihara; Y Miyazaki Journal: Leukemia Date: 2014-01-10 Impact factor: 11.528
Authors: V I Gaidzik; D Weber; P Paschka; A Kaumanns; S Krieger; A Corbacioglu; J Krönke; S Kapp-Schwoerer; D Krämer; H-A Horst; I Schmidt-Wolf; G Held; A Kündgen; M Ringhoffer; K Götze; T Kindler; W Fiedler; M Wattad; R F Schlenk; L Bullinger; V Teleanu; B Schlegelberger; F Thol; M Heuser; A Ganser; H Döhner; K Döhner Journal: Leukemia Date: 2017-06-23 Impact factor: 11.528
Authors: Zejuan Li; Tobias Herold; Chunjiang He; Peter J M Valk; Ping Chen; Vindi Jurinovic; Ulrich Mansmann; Michael D Radmacher; Kati S Maharry; Miao Sun; Xinan Yang; Hao Huang; Xi Jiang; Maria-Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann; Abdel Elkahloun; Mary Beth Neilly; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Konstanze Döhner; Lars Bullinger; Paul P Liu; Ruud Delwel; Guido Marcucci; Bob Lowenberg; Clara D Bloomfield; Janet D Rowley; Stefan K Bohlander; Jianjun Chen Journal: J Clin Oncol Date: 2013-02-04 Impact factor: 44.544